Licart is a drug owned by Ibsa Institut Biochimique Sa. It is protected by 2 US drug patents filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 20, 2035. Details of Licart's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11351133 | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | Active |
| US11344520 | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Licart's patents.
Latest Legal Activities on Licart's Patents
Given below is the list of recent legal activities going on the following patents of Licart.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 25 May, 2023 | US11351133 |
| Mail Certificate of Correction Memo | 24 May, 2023 | US11351133 |
| Post Issue Communication - Certificate of Correction | 22 May, 2023 | US11351133 |
| Certificate of Correction Memo | 22 May, 2023 | US11351133 |
| Recordation of Patent Grant Mailed Critical | 07 Jun, 2022 | US11351133 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Jun, 2022 | US11351133 |
| Recordation of Patent Grant Mailed Critical | 31 May, 2022 | US11344520 |
| Patent Issue Date Used in PTA Calculation Critical | 31 May, 2022 | US11344520 |
| Email Notification Critical | 19 May, 2022 | US11351133 |
| Issue Notification Mailed Critical | 18 May, 2022 | US11351133 |
FDA has granted several exclusivities to Licart. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Licart, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Licart.
Exclusivity Information
Licart holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Licart's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 19, 2021 |
US patents provide insights into the exclusivity only within the United States, but Licart is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Licart's family patents as well as insights into ongoing legal events on those patents.
Licart's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Licart's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 20, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Licart Generics:
There are no approved generic versions for Licart as of now.
Alternative Brands for Licart
Licart which is used for alleviating acute pain from minor strains, sprains, and contusions through once daily application of a diclofenac patch containing heparin without releasing heparin., has several other brand drugs using the same active ingredient (Diclofenac Epolamine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Ibsa |
|
About Licart
Licart is a drug owned by Ibsa Institut Biochimique Sa. It is used for alleviating acute pain from minor strains, sprains, and contusions through once daily application of a diclofenac patch containing heparin without releasing heparin. Licart uses Diclofenac Epolamine as an active ingredient. Licart was launched by Ibsa Inst Bio in 2018.
Approval Date:
Licart was approved by FDA for market use on 19 December, 2018.
Active Ingredient:
Licart uses Diclofenac Epolamine as the active ingredient. Check out other Drugs and Companies using Diclofenac Epolamine ingredient
Treatment:
Licart is used for alleviating acute pain from minor strains, sprains, and contusions through once daily application of a diclofenac patch containing heparin without releasing heparin.
Dosage:
Licart is available in system form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.3% | SYSTEM | Prescription | TOPICAL |